Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Strong growth
About
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued
Target Price
The average target price of XVIVO.ST is 341 and suggests 80% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell